User | malvern-online.com - Latest News about Fulcrum Therapeutics, Inc. - Common Stock (Nasdaq:FULC) | Fulcrum Therapeutics, Inc. - Common Stock (Nasdaq:FULC) News

Skip to main content

Sign Up
Log In

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home

News

Sports

Obituaries

Photos

e-Edition

Classifieds

Archives

Readers Choice 2026

Subscribe

- Site search

Contact Us
Subscribe
e-Edition

Sign Up
Log In

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Site search

75° Partly Cloudy
- Malvern, AR (72104)
  Today
  
  Mostly cloudy early with scattered thunderstorms developing this afternoon. High 92F. Winds light and variable. Chance of rain 60%..
  
  Recent Quotes
  
  View Full List
  
  My Watchlist
  
  Create Watchlist
  
  Indicators
  
  DJI
  
  Nasdaq Composite
  
  SPX
  
  Gold
  
  Crude Oil
  
  Markets
  
  Stocks
  
  ETFs
  
  Tools
  
  Markets:
  
  Overview
  
  News
  
  Currencies
  
  International
  
  Treasuries
  
  Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)
  
  3.720 +0.100 (+2.76%)
  Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist
  
  Quote
  Overview Detailed Quote Charting Historical Prices
  
  News
  All News News Headlines Press Releases
  
  Research
  Quarterly Reports Insider Filings Other Filings
  
  All News about Fulcrum Therapeutics, Inc. - Common Stock
  
  < Previous 1 2 3 4 5 6 7 8 9
  ...
  13 14 Next >
  
  Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views ↗
  September 13, 2024
  
  Via Benzinga
  
  Dow Surges Over 100 Points; ModivCare Shares Plummet ↗
  September 12, 2024
  
  Via Benzinga
  
  Topics Stocks
  
  FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
  September 12, 2024
  
  From The Schall Law Firm
  
  Via Business Wire
  
  Crude Oil Surges 3%; Kroger Posts Upbeat Earnings ↗
  September 12, 2024
  
  Via Benzinga
  
  Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
  May 13, 2024
  
  Via Benzinga
  
  Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
  April 12, 2024
  
  Via Investor Brand Network
  
  Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial ↗
  September 12, 2024
  
  Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.
  
  Via Benzinga
  
  US Stocks Mixed; Producer Prices Increase In August ↗
  September 12, 2024
  
  Via Benzinga
  
  Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
  September 12, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗
  September 09, 2024
  
  BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in...
  
  Via Benzinga
  
  Fulcrum Therapeutics to Participate in Upcoming September Conferences
  August 27, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  August 23, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
  August 19, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  August 09, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  8 Health Care Stocks With Whale Alerts In Today's Session ↗
  August 01, 2024
  
  Via Benzinga
  
  Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
  July 31, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
  July 24, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter ↗
  July 16, 2024
  
  Via Benzinga
  
  Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
  June 12, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  10 Health Care Stocks With Whale Alerts In Today's Session ↗
  June 11, 2024
  
  Via Benzinga
  
  Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
  June 06, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 ↗
  May 13, 2024
  
  FULC stock results show that Fulcrum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
  
  Via InvestorPlace
  
  12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
  May 13, 2024
  
  Via Benzinga
  
  Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
  May 13, 2024
  
  It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
  
  Via InvestorPlace
  
  Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
  May 13, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
  May 13, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics to Participate in Upcoming May Conferences
  May 09, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
  May 08, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
  May 06, 2024
  
  From Fulcrum Therapeutics, Inc.
  
  Via GlobeNewswire
  
  Biotech on a Budget: 7 Stocks Under $10 With Huge Potential ↗
  April 15, 2024
  
  With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
  
  Via InvestorPlace
  
  < Previous 1 2 3 4 5 6 7 8 9
  ...
  13 14 Next >
  
  Stock Quote API & Stock News API supplied by www.cloudquote.io
  Quotes delayed at least 20 minutes.
  By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  © 2025 FinancialContent. All rights reserved.